These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1904357)

  • 1. Comparison of different HMG-CoA reductase inhibitors.
    Ditschuneit HH; Kuhn K; Ditschuneit H
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S27-32. PubMed ID: 1904357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of new drugs for lowering plasma cholesterol concentrations.
    Illingworth DR
    Drugs; 1991 Feb; 41(2):151-60. PubMed ID: 1709846
    [No Abstract]   [Full Text] [Related]  

  • 3. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 4. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin and simvastatin for hypercholesterolemia.
    Med Lett Drugs Ther; 1991 Mar; 33(839):18-20. PubMed ID: 1899899
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
    Lintott CJ; Scott RS; Sutherland WH; Bremer J
    Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
    Sasaki S; Sawada S; Nakata T; Itoh H; Takeda K; Nakagawa M; Kuriyama K
    J Cardiovasc Pharmacol; 1997 Jul; 30(1):142-7. PubMed ID: 9268234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
    Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W; Bimmermann A; Schleicher J
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
    Lambrecht LJ; Malini PL
    Acta Cardiol; 1993; 48(6):541-54. PubMed ID: 8122478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercholesterolemia: therapeutic approach].
    Alessandri C; Peverini F
    Clin Ter; 1991 Jun; 137(6):373-97. PubMed ID: 1832610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
    Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N; Homma Y; Tamachi H; Shigematsu H; Hata Y; Goto Y
    JAMA; 1987 Jun; 257(22):3088-93. PubMed ID: 3108527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.